Indication includes adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, for LDL-C ...
Pharmaceutical Executive recently spoke with Nuvation Bio’s president, CEO, and founder David Hung. The growing biotech is ...
A two-track structure combines AI-native target discovery and generative chemistry with formulation, CMC, regulatory strategy, tech transfer, scale-up, and commercial supply to shorten the molecule-to ...
Approval is backed by VIKTORIA-1 (PIK3CA wild-type), a global open-label randomized trial of gedatolisib plus fulvestrant ± palbociclib after progression on CDK4/6 therapy and an aromatase inhibitor.
Pharmaceutical Executive recently spoke with Nuvation Bio’s president, CEO, and founder David Hung. The growing biotech is ...
Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...
LillyDirect exemplifies DTP as a demand-unlocking commercial channel rather than a compliance tactic, with executives ...
It is also why I have spent over fifteen years building around a conviction the healthcare industry still resists: when ...
Sanofi Chief Digital Officer Emmanuel Frenehard on scaling AI across a Big Pharma global enterprise and why a strategy of ...
All-stock combination targets Nasdaq listing as “SCIP,” with expected close Q4 2026 and runway through 2H 2028 from a ~$30M syndicate financing. Nebokitug, a first-in-class anti-CCL24 mAb, is ...
In today's Pharmaceutical Executive Daily, FDA approves Ennumo, a pharma roundup covers Chemomab Therapeutics' merger with AI ...
Once-weekly subcutaneous initiation dosing offers an at-home alternative for adults with MCI or mild dementia due to Alzheimer’s disease, potentially reducing infusion-center dependence and visit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results